10 AI-Analyzed Biotech Signals
for $9

Filing: Q4 2025 results and obesity pipeline update

Viking's February 11 8-K said it ended 2025 with $706.0 million of cash, cash equivalents, and short-term investments. The same filing said oral VK2735 is set to enter Phase 3 in 3Q26 while the subcutaneous VANQUISH obesity program remains underway with VANQUISH-1 fully enrolled and VANQUISH-2 nearing full enrollment. A $345.0 million 2025 R&D budget is large, but the balance sheet still leaves meaningful room to carry the obesity catalyst cycle.

Filing: Q4 2025 revenue and commercial update

BridgeBio's February 24 filing reported $587.5 million of cash, cash equivalents, and marketable securities at year-end and $502.1 million of full-year 2025 revenue, including $146.0 million of net product revenue in the fourth quarter. Management also said the company added $632.5 million of 2033 convertible notes in January 2026 and highlighted three positive Phase 3 readouts in just over three months. That combination of revenue scale, financing access, and late-stage data keeps the signal skewed positive despite a $724.9 million annual net loss.

Filing: Q4 2025 results and Hunter syndrome launch readiness

Denali reported approximately $966.2 million of cash, cash equivalents, and marketable securities in its February 26 8-K. The filing also said launch readiness is in place ahead of the April 5, 2026 PDUFA target action date for tividenofusp alfa in Hunter syndrome, while the global Phase 2/3 COMPASS study finished Cohort A enrollment in December 2025. That gives traders a real regulatory catalyst with enough liquidity to carry the commercial setup.